Impact Partnership Wealth LLC Takes Position in Jazz Pharmaceuticals PLC $JAZZ

Impact Partnership Wealth LLC bought a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,620 shares of the specialty pharmaceutical company’s stock, valued at approximately $278,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Philip James Wealth Mangement LLC increased its position in Jazz Pharmaceuticals by 42.0% during the 2nd quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock worth $1,676,000 after purchasing an additional 4,675 shares in the last quarter. State of Alaska Department of Revenue increased its position in Jazz Pharmaceuticals by 75.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock worth $6,147,000 after purchasing an additional 24,850 shares in the last quarter. Inspire Investing LLC acquired a new position in Jazz Pharmaceuticals during the 1st quarter worth approximately $689,000. Baird Financial Group Inc. acquired a new position in Jazz Pharmaceuticals during the 1st quarter worth approximately $539,000. Finally, Voya Investment Management LLC increased its position in Jazz Pharmaceuticals by 67.1% during the 1st quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company’s stock worth $6,996,000 after purchasing an additional 22,628 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Up 0.4%

Shares of NASDAQ JAZZ opened at $136.30 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The firm has a 50 day moving average price of $131.90 and a two-hundred day moving average price of $117.88. The stock has a market cap of $8.27 billion, a P/E ratio of -20.25, a price-to-earnings-growth ratio of 8.49 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the prior year, the company posted $5.30 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, equities analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 3,500 shares of the company’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total value of $490,000.00. Following the sale, the director directly owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. This represents a 0.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 11,500 shares of company stock valued at $1,525,280. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of a number of research analyst reports. Royal Bank Of Canada upped their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a research report on Thursday, August 28th. JPMorgan Chase & Co. lowered their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price target for the company. Finally, Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Fourteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $179.33.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.